Medpage Today on MSN14 天
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast Cancer
The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, ...
Medscape7 天
T-DXd Shows Consistent Benefit Across Endocrine-Resistant HR+/HER2-Low Breast Cancer Subgroups
New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...
Medscape6 天
New Classification of HER2–Ultra-Low Breast Cancer: What Do We Need to Know?
Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.
pharmaphorum5 天
ASCO22: Enhertu aces key HER2-low test in breast cancer
The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...
pharmaphorum4 天
EU clears Enhertu for HER2-low breast cancer
In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between ...
precisionmedicineonline12 天
SABCS Studies Highlight Novel HER2 Therapies in Frontline Setting, HER2-Low, Brain Metastases
Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.